ADMA Biologics, Inc. announced that it has received U.S. Food and Drug Administration ("FDA") approval for its tenth ADMA BioCenters plasma collection facility located in Laurel, Maryland. This plasma collection facility commenced operations and initiated source plasma collection in the first half of 2023. With the FDA approval announced, this facility is now licensed to introduce into interstate commerce human source plasma for further manufacturing in the U.S. This new plasma collection center features automated registration, high-tech collection equipment designed to shorten the donation process, free Wi-Fi wireless network in the donor collection area, individual flat-screen TVs with cable at each donor station, and highly trained and certified staff who put donor comfort and safety first.

At full capacity, the plasma center expects to maintain a staff of 50 highly trained healthcare workers. This center is approved to use the Haemonetics NexSys Persona(R) plasma collection system.